Home' Australian Pharmacist : March 2011 Contents Vol. 30 -- March #03
between Session 2 and Sessions 3
or 4, therefore the value of additional
sessions seems to be minimal.
However, it may be a little premature
to discard additional sessions as the
numbers are low, with more recent
cases still to progress to the 24 week
and 48 week sessions.
Even though these data suggest that
two sessions might be most feasible,
this study did not assess whether
their improved compliance following
two sessions only is maintained in the
longer term (e.g. 12 months).
There were similar improvements
in the MI scores from baseline
(Session 1) between the branded
medicines (28% to 30%) and the
generic medicines (25% to 36%).
This suggests that improvements in
compliance from pharmacist coaching
sessions did not seem to be affected
by high profile brand names.
The data in this study only reflect
the first year of the Mirixa Australia
programs. It seems reasonable to
expect that as pharmacists' skill to
encourage and help patients to take
the medication improves so will the
patient's medication consumption
At this early stage, there seem to be
clear financial benefits for pharmacies
as the intervention translates into
an increase of 1.5 prescriptions per
patient per year after the intervention
at Session 1. Based on the increase
in prescription numbers alone, this
translates into around $15 in extra
margin (dispensing fee and mark-up)
per patient completing Session 1,
and given the continued low level of
compliance, this could be expected
to increase further once pharmacists
improve case identification and refine
their education strategies. In addition,
engaging and retaining non-compliant
patients may also improve customer
loyalty as more of these patients will
return to the same pharmacy more
This shows that in the first 12 months
of operation, the Mirixa Australia
programs have delivered on the promise
of improved compliance by patients as
well as increased prescriptions for the
1. Pharmacy Guild of Australia. MedsIndex: A Medicines
Compliance Indicator. Mar 2008.
2. Haynes RB, Ackloo E, Sahota N, et al. Interventions for
enhancing medication adherence. Cochrane Database
of Systematic Reviews 2008, Issue 2.
3. Roughead EE, Semple SJ, Vitry A. The value of
pharmacist professional services in the community
setting: A systematic review of the literature 1990--
2002. Canberra: Pharmacy Guild of Australia; 2002.
4. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care
program on medication adherence and persistence,
blood pressure, and low-density lipoprotein cholesterol.
JAMA. 2006; 296:2563--2571.
5. Odegard PS. Presentation at the 2010 annual meeting
of the American Association of Diabetes Educators.
6. Krass I, Taylor SJ, Smith C, et al. Impact on medication
use and adherence of Australian pharmacists' diabetes
care services. J Am Pharm Assoc. 2005 Jan-Feb;
7. Aslani P, Rose, Chen T, et al. A community pharmacist
delivered adherence support service for dyslipidaemia
[online]. Eur J Public Health. 3 Sep 2010.
8. Feyer A, Schulman C, Jessop R, et al. National trial
to test strategies to improve medication compliance
in a community pharmacy setting -- full report. The
Pharmacy Guild of Australia; 2010.
WA pharmacists get
new asthma tools
WA pharmacists have been
provided a new asthma tool as a
result of local asthma research.
The project officer for the statewide
launch of a new Asthma Action
Plan card and Beta Agonist
Guidelines, Kim Watkins said that
the Guidelines were developed
as a result of PhD research by
Carl Schneider at the University
of Western Australia which found
inadequacies in the way community
pharmacists were handling the OTC
sale of asthma reliever medications.
'Integral to the Guidelines was the
need for patients to be referred to a
medical practitioner if they did not
have a written Asthma Action Plan.
This led researchers to collaborate
with the WA Department of Health's
Respiratory Health Network and
the Asthma Foundation of WA (and
all its incumbent stakeholders),
to develop a patient card that
would support the Guidelines for
Pharmacists and also the objectives
of the Department's Asthma Model
of Care document.
'The launch project was a massive
undertaking as all pharmacists across
Western Australia needed to be
provided with Asthma Action plan
cards and education about their use
in conjunction with the Guidelines. So
far more than 20,000 cards have been
distributed to pharmacies in WA,
The Pharmaceutical Society of
Western Australia (PSWA) could
see the the potential of the tools to
greatly improve professional practice
and in a first ever initiative agreed
to fund personal detailing of every
metropolitan pharmacy in Perth
(400 pharmacies). This included the
development of a resource booklet
and training for pharmacist detailers.
Following the success of the
metropolitan program GlaxoSmithKline
agreed to finance a rural launch
package which was distributed to
every rural pharmacy across WA.
Information has also been distributed
via lectures, emails and even interns
conducting 'in house' training in their
Pharmaceutical Society of Western
Australia committee member, Amanda
Bryce said the cards would provide a
good opportunity for pharmacists
to engage with patients who had
not recognised the importance of
managing their condition.
'Many customers admit to not
having an asthma action plan and
aren't aware that developing a
cough overnight or needing to use
their Ventolin more than twice a
week are red flags for uncontrolled
asthma. By recording a person's
medication each time they come
to buy a reliever refill, pharmacists
can ensure their customers are
receiving the appropriate dosage. If
a pharmacist notices that there has
been overuse of reliever medication
or any other anomalies in the use of
asthma medication, they can refer
the customer to their GP for an
asthma medication review'.
Ms Watkins said the next
phase of the implementation
involves informing consumers
and other health professionals.
The WA Health Department has
provided resources from its
Communications Directorate and
the Asthma Foundation of WA has
also distributed information to
consumers through its newsletter.
Links Archive April 2011 Australian Pharmacist February 2011 Navigation Previous Page Next Page